1. Economic Costs of Bads © Allen C. Goodman, 2010

2. Leading Cause of Preventable Death in U.S. Cigarette smoking is the leading cause of preventable death in the United States and produces substantial health-related economic costs to society. CDC calculated national estimates of annual smoking- attributable mortality (SAM), years of potential life lost (YPLL), smoking-attributable medical expenditures (SAEs) for adults and infants, and productivity costs for adults. Results show that during 2000-2004, smoking caused approximately 390,000 premature deaths in the United States annually and approximately $193 billion in annual health-related economic losses. Implementation of comprehensive tobacco-control programs as recommended by CDC could effectively reduce the prevalence, disease impact, and economic costs of smoking. https://apps.nccd.cdc.gov/sammec/reports.asp

4. Source: NESARC Database

6. Disease CategoryMaleFemaleTotal Malignant Neoplasms Lip, Oral Cavity, Pharynx3,7491,1444,893 Esophagus6,9611,6318,593 Stomach1,9005842,484 Pancreas3,1473,5366,683 Larynx2,4465633,009 Trachea, Lung, Bronchus78,68046,842125,522 Cervix Uteri0447 Kidney and Renal Pelvis2,8272163,043 Urinary Bladder3,9071,0764,982 Acute Myeloid Leukemia8553371,193 Subtotal104,47256,376160,849 Average Annual Smoking-Attributable Mortality (United States, 2000-2004)

7. Cardiovascular Diseases Ischemic Heart Disease50,88429,12180,005 Other Heart Disease12,9448,06021,002 Cerebrovascular Disease7,8968,02615,922 Atherosclerosis1,2826111,893 Aortic Aneurysm5,6282,7918,418 Other Circulatory Diseases5057491,254 Subtotal79,13949,358128,494 Respiratory Diseases Pneumonia, Influenza6,0424,38110,423 Bronchitis, Emphysema7,5366,39113,927 Chronic Airway Obstruction40,21738,77178,988 Subtotal53,79549,543103,338 Average Annual Total237,406155,277392,681 Male Female

8. Average Annual Smoking-Attributable Years of Potential Life Lost (United States, 2000-2004) 1,2 Disease CategoryMaleFemaleTotal Malignant Neoplasms Lip, Oral Cavity, Pharynx65,33619,04784,383 Esophagus108,84725,382134,229 Stomach27,6028,97136,573 Pancreas50,20153,334103,535 Larynx38,0129,91447,926 Trachea, Lung, Bronchus1,118,359770,6551,889,014 Cervix Uteri011,918 Kidney and Renal Pelvis43,8983,72247,620 Urinary Bladder44,16613,24557,411 Acute Myeloid Leukemia12,5275,49618,023 Subtotal1,508,948921,6842,430,632 Average Annual Smoking-Attributable Years of Potential Life Lost (United States, 2000-2004) 1,2

9. Cardiovascular Diseases Ischemic Heart Disease804,551389,9741,194,525 Other Heart Disease55,62131,74587,366 Cerebrovascular Disease127,280140,894268,174 Atherosclerosis11,8145,47517,289 Aortic Aneurysm70,51234,192104,704 Other Circulatory Diseases6,6369,38616,022 Subtotal1,076,414611,6661,688,080 Respiratory Diseases Pneumonia, Influenza29,82823,43853,266 Bronchitis, Emphysema42,84240,84483,686 Chronic Airway Obstruction421,721462,973884,694 Subtotal494,391527,2551,021,646 Average Annual Total3,079,7532,060,6055,140,358 Male Female

10. Average Annual Smoking- Attributable Productivity Losses The economic costs of lost work time among adults because of deaths from smoking. Productivity losses in Adult SAMMEC are defined as the present value of estimated loss of future earnings from paid work and the estimated imputed value of future unpaid household work attributable to premature deaths from smoking.

11. Average Annual Smoking-Attributable Productivity Losses (United States, 2000- 2004) 1,2,3 Disease CategoryMaleFemaleTotal Malignant Neoplasms Lip, Oral Cavity, Pharynx1,613,319354,6351,967,954 Esophagus2,464,063433,2732,897,336 Stomach600,702157,891758,593 Pancreas1,162,577884,7612,047,338 Larynx853,914186,3171,040,231 Trachea, Lung, Bronchus23,189,09613,597,33336,786,429 Cervix Uteri0307,412 Kidney and Renal Pelvis997,06270,6801,067,742 Urinary Bladder742,898174,529917,427 Acute Myeloid Leukemia272,42999,772372,201 Subtotal31,896,06016,266,60348,162,663

12. Cardiovascular Diseases Ischemic Heart Disease19,019,0626,068,24225,087,304 Other Heart Disease1,134,588428,0841,562,672 Cerebrovascular Disease3,075,3042,878,0175,953,321 Atherosclerosis155,19840,423195,621 Aortic Aneurysm1,339,220445,6251,784,845 Other Circulatory Diseases134,357133,702268,059 Subtotal24,857,7299,994,09334,851,822 Respiratory Diseases Pneumonia, Influenza448,507273,061721,568 Bronchitis, Emphysema708,007532,1621,240,169 Chronic Airway Obstruction6,306,5435,545,30411,851,847 Subtotal7,463,0576,350,52713,813,584 Average Annual Total64,216,84632,611,22396,828,069 Male Female

13. Methods of Analysis (1) The disease impact of smoking was estimated by using the Adult and Maternal and Child Health Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC) software (4). Smoking-attributable deaths were calculated by multiplying estimates of the smoking-attributable fraction (SAF) of preventable deaths by total mortality data for 18 adult and four infant causes of death. For adults, SAFs were derived by using relative risks (RRs) for each cause of death and current and former cigarette smoking prevalence for two age cohorts: persons aged 35--64 years and persons aged >65 years.

14. For infants, SAFs were calculated by using RRs of death for infants of women who smoked during pregnancy and maternal smoking rates from birth certificates Smoking-attributable YPLL and productivity costs were estimated by multiplying age- and sex-specific SAM by remaining life expectancy and lifetime earnings data, respectively. Smoking-attributable fire deaths were included in the SAM and YPLL estimates. SAM included lung cancer and heart disease deaths attributable to exposure to secondhand smoke. Methods of Analysis (2)

15. CDC Viewpoint Cigarette smoking continues to be the principal cause of premature death in the United States and imposes substantial costs on society. Cigarette smoking continues to result in substantial costs. The economic costs of smoking in the United States are estimated at $193 billion annually ($96.8 billion in productivity losses from premature death and $96 billion in health-care expenditures)

16. References CDC. Smoking-attributable mortality and years of potential life lost---United States, 1984. MMWR 1997;46:444--51. Max W. The financial impact of smoking on health-related costs: a review of the literature. Am J Health Promot 2001;15:321--31. CDC. Best practices for comprehensive tobacco control programs---August 1999. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 1999. CDC. Smoking-attributable mortality, morbidity, and economic costs (SAMMEC): adult SAMMEC and maternal and child health (MCH) SAMMEC software, 2002. Available at http://www.cdc.gov/tobacco/sammec. Thun MJ, Day-Lally C, Myers DG, et al. Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). In: Changes in cigarette-related disease risks and their implication for prevention and control. Smoking and tobacco control monograph 8. Bethesda, Maryland: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1997; 305--82. Hall JR. The U.S. smoking-material fire problem. Quincy, Massachusetts: National Fire Protection Association, Fire Analysis and Research Division, 2001. National Cancer Institute. Health effects of exposure to environmental tobacco smoke: the report of the California Environmental Protection Agency. Smoking and tobacco control monograph 10. Bethesda, Maryland: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 1999. Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. Soc Sci Med 1999;48:375--91. CDC. Declines in lung cancer rates---California, 1988--1997. MMWR 2000;49:1066--9. Fichtenberg CM, Glantz SA. Association of the California Tobacco Control Program with declines in cigarette consumption and mortality from heart disease. N Engl J Med 2000;343:1772--7. Also, Surgeon General’s 2004 Report at http://www.cdc.gov/tobacco/sgr/sgr_2004/index.htm

17. Alcohol and Drugs Key issues involve defining costs. Property theft, for example, is an economic cost ONLY to the extent that it leads to increased resources needed to prevent it, or to punish perpetrators. Otherwise it is a transfer.

18. Substance Abuse Costs For substance abuse and substance abuse treatment, one must be careful in defining the internal and the external costs and benefits. Substance abuse imposes three major costs that are fundamentally internal to the individual and his or her family. –Reduced productivity on the job, and hence reduced earnings. –Reduced health for the individual, even if his or her earnings are not affected. –Earlier death.

19. Substance Abuse Costs (2) Assuming that these costs are understood, the individual and his/her family choose or choose not to treat substance abuse conditions. There are, however, external costs attributable to substance abuse. Drinking may lead to violence against other people, and drunken drivers kill innocent people on the highways. Drinking, by itself or in concert with other substance abuse, may lead to criminal activity. Pregnant women who drink risk damage to their unborn children. These items suggest that there may be a societal choice to provide alcohol and substance abuse treatments even to those who would not choose it for themselves.

22. Interventions Fleming and colleagues (2000) evaluated a brief intervention remedy to at-risk or problem drinking. The study was confined to problem drinkers, defined as men who consumed more than 14 drinks per week (168 g alcohol/week) and women who consumed more than 11 drinks per week (132 g alcohol/week). There are six essential components to brief intervention. Physician: 1. States his/her concern. 2. Provides specific feedback to patients on how their drinking is affecting them (e.g. elevated blood pressure, liver function problems, family problems). 3. Gives a clear recommendation about changing patients’ alcohol use. 4. Negotiates a drinking contract. 5. Provides a self-help booklet. 6.Establishes follow-up procedures.

23. Benefits and Costs Study team assessed the benefits and costs of brief intervention, including emergency room and outpatient and inpatient hospital use, automobile accidents and traffic violations, criminal activity, alcohol and substance use, and health status measures. The costs were measured for those who participated in the intervention. The benefits are reported as avoided costs, comparing the 392 study patients with a randomized control group (382 patients). The researchers report a benefit-cost ratio of 5.6:1. The benefits included savings of $195 thousand in emergency room and hospital use and $228 thousand in avoided costs resulting from motor vehicle events and crime for a combined economic benefit of $1,151 per subject. The estimated total economic cost of the intervention was $80 thousand or $205 per study patient.

24. Evaluation of Evaluation This study illustrates the importance of evaluating external effects. Of the $1,151 in benefits per subject, $620, or 54% were attributable to factors external to the individual, although the authors acknowledge a wide confidence interval around this point estimate. Nonetheless, this finding suggests the importance of a public health intervention rather than a simple individual decision as to whether to get treatment. An economist also asks questions when seeing a benefit-cost ratio of 5.6:1. If this measured ratio is a valid one, then why do we not see these types of programs for treating large numbers of alcoholics? Indeed why aren’t the insurers demanding that such programs be established? The Fleming study finds that from the perspective of the managed care organization (excluding the external benefits) the benefit cost ratio was 3.2:1.

25. References Fleming MF, Mundt MP, French MT, Barry KL, Manwell LB, Stauffacher EA. 2000. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Medical Care 38 (1): 7-18. Folland S, Goodman A, Stano M. The Economics of Health and Health Care, Upper Saddle River NJ: Prentice Hall, 2001. French MT. 2000. Economic evaluation of alcohol treatment services. Evaluation and programming planning, 23 (1): 27-39. Goodman AC, Nishiura E, Humphreys RS. 1997. Cost and usage impacts of treatment initiation: a comparison of alcoholism and drug abuse treatments. Alcohol Clin. Exp. Res., 21 931-938. Harwood H, Fountain D, Livermore G. The Economic Costs of Alcohol and Drug Abuse in the United States, 1992. http://www.nida.nih.gov/EconomicCosts/. Jones KR, Vischi TR (1979) Impact of alcohol, drug abuse and mental health treatment on medical care utilization Medical Care 17: 1. Yates BT. Measuring and Improving Cost, Cost-Effectiveness, and Cost-Benefit for Substance Abuse Treatment Programs. Bethesda MD: National Institute on Drug Abuse, 1999.

26. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5114a2.htm Smoking-attributable mortality (SAM), Years of potential life lost (YPLL), Smoking-attributable medical expenditures (SAEs)

27. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5114a2.htm